OGN Stock: Price, Earnings History and SEC Filings
Organon & Co. (OGN) last traded at $13.84, up 0.22% on the latest session and up 1.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.80 against an analyst estimate of $0.85, a miss of 5.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
OGN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 31, 2026 | $0.80 | $0.85 | -5.88% |
| Mar 2026 | Apr 30, 2026 | $0.66 | $0.82 | -19.51% |
| Dec 2025 | Feb 12, 2026 | $0.61 | $0.70 | -12.86% |
| Sep 2025 | Nov 10, 2025 | $0.93 | $0.90 | +3.33% |
OGN beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How OGN reacts to earnings
Across its last 8 earnings releases, OGN moved 10.8% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-04-30 | Before open | -0.67% |
| 2026-02-12 | Before open | -8.19% |
| 2025-11-10 | Before open | +13.72% |
| 2025-08-05 | Before open | -13.13% |
| 2025-05-01 | Before open | -26.91% |
| 2025-02-13 | Before open | +11.02% |
| 2024-10-31 | Before open | +4.74% |
| 2024-08-06 | Before open | -7.63% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
OGN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $6.2B | $187M | $538M | 3.0% | $0.72 |
| 2024 | $6.4B | $864M | $764M | 13.5% | $3.33 |
| 2023 | $6.3B | $1.0B | $548M | 16.3% | $3.99 |
| 2022 | $6.2B | $917M | $662M | 14.9% | $3.59 |
| 2021 | $6.3B | $1.4B | – | 21.4% | $5.31 |
| 2020 | $6.5B | $2.2B | – | 33.1% | $8.52 |
| 2019 | $7.8B | $3.2B | – | 41.4% | $12.69 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for OGN
- 8-K · Oct 30, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Oct 30, 2026
- 8-K · Jul 31, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Jul 31, 2026
- 8-K · Jul 23, 2026Shareholder vote
- 8-K · Jul 17, 2026Other events
- 8-K · Jun 11, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 4, 2026
- 8-K · Apr 30, 2026Results of operations, Financial statements and exhibits
- 8-K · Apr 27, 2026Material agreement, Officer or director change, Regulation FD disclosure
Insider filing activity
OGN insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
OGN news
- Organon (OGN) Q3 Results Highlight A Thin Margin CushionNov 1, 2026 · finance.yahoo.com
- Organon (OGN) Q3 Earnings and Revenues Top EstimatesOct 30, 2026 · finance.yahoo.com
- Organon: Q3 Earnings SnapshotOct 30, 2026 · finance.yahoo.com
- Organon Announces Quarterly DividendOct 30, 2026 · finance.yahoo.com
- Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of DirectorsOct 27, 2026 · finance.yahoo.com
- Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on ItOct 26, 2026 · finance.yahoo.com
- Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q FilingOct 19, 2026 · finance.yahoo.com
About Organon & Co.
Organon & Co. (OGN) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.